04/30/2026
NovaBridge Biosciences and Visara reported promising early results for VIS-101, a potential new treatment for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Learn more: https://www.ophthalmologytimes.com/view/novabridge-visara-report-positive-phase-2a-results-for-dual-vegf-a-ang-2-inhibitor-vis-101
The phase 2a study looks at retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).